title: Protein kinase R plays a pivotal role in oncostatin M and interleukin-1 signalling in bovine articular cartilage chondrocytes.
abstract: This study investigated whether treatment of articular cartilage chondrocytes with a combination of oncostatin M (OSM) and interleukin-1 (IL-1) could induce a degradative phenotype that was mediated through the protein kinase R (PKR) signalling pathway. High-density monolayer cultures of full depth, bovine chondrocytes were treated with a combination of OSM and IL-1 (OSM+IL-1) for 7 days. To inhibit the activation of PKR, a pharmacological inhibitor of PKR was added to duplicate cultures. Pro- and active matrix metalloproteinase-9 (MMP9) and MMP9 mRNA were significantly upregulated by OSM+IL-1 through a PKR dependent mechanism. ADAMTS4 and ADAMTS5 mRNA were also upregulated by OSM+IL-1. The upregulation of ADAMTS4 and ADAMTS5 were, in part, mediated through PKR. OSM+IL-1 resulted in a loss of type II collagen, which could not be rescued by PKR inhibition. OSM+IL-1 reduced the expression of COL2A1 (type II collagen), COL9A1 (type IX collagen), COL11A1 (type XI collagen), and ACAN (aggrecan) mRNAs. Expression of type II and XI collagen and aggrecan was reduced further when PKR was inhibited. OSM+IL-1 resulted in an 11-fold increase in TNFa mRNA which was, in part, mediated through the PKR pathway. This study demonstrates, for the first time, that a number of catabolic and pro-inflammatory effects known to be important in human arthritis and induced by OSM and IL-1, are mediated by the PKR signalling pathway.
authors.affiliation: School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, Wales, UK. gilbertsj1@Cardiff.ac.uk
authors.forename: S J
authors.initials: SJ
authors.lastname: Gilbert
authors.forename: E J
authors.initials: EJ
authors.lastname: Blain
authors.forename: A
authors.initials: A
authors.lastname: Al-Sabah
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: V C
authors.initials: VC
authors.lastname: Duance
authors.forename: D J
authors.initials: DJ
authors.lastname: Mason
mesh_terms: D051722:ADAM Proteins / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002358:Cartilage, Articular / Q000166:cytology* / Q000378:metabolism*; D002417:Cattle; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism*; D024043:Collagen Type II / Q000187:drug effects / Q000378:metabolism; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D007375:Interleukin-1 / Q000008:administration & dosage*; D053509:Matrix Metalloproteinase 13 / Q000187:drug effects / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000187:drug effects / Q000378:metabolism; D053683:Oncostatin M / Q000008:administration & dosage* / Q000378:metabolism*; D061251:Primary Cell Culture; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019892:eIF-2 Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D024043:Collagen Type II; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D007375:Interleukin-1; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D053683:Oncostatin M; D019892:eIF-2 Kinase; D051722:ADAM Proteins; D053509:Matrix Metalloproteinase 13; D020780:Matrix Metalloproteinase 9